Changing Systems, One Story at a Time: National Summit Reimagines Obesity Care Through Community, Connection, and Compassion
With the theme "Inspire Change. Build Connection. Advance Wellness.", the summit brings together healthcare professionals, lived experience advocates, and community leaders to explore how we can shift the narrative around health — from judgment to empathy, and from isolation to meaningful support.
"Obesity isn't a character flaw — it's a chronic condition that deserves empathy, science, and dignity," says Priti Chawla, Executive Director of Obesity Matters.
"This summit is about rewriting the narrative — one story, one connection, one person at a time."
Program highlights include:
Dr. Sean Wharton and Dr. Gillian Mandich on self-compassion and emotional resilience
Dr. Megha Poddar on hormone health across life stages
Dr. Peter Selby facilitating a storytelling session with patient advocates
Dr. David Macklin on Resilience… The Secret Skill to Success
A featured session on Body Image, Stigma, and the Age of Anti-Obesity Medication will be led by Dr. Sandy Van and Sandra Elia, Chair of Obesity Matters.
"We can't let outdated ideals or social media define what health looks like," says Dr. Sandy Van.
"In the era of obesity medication, the pressure to meet unrealistic appearance goals can take a real psychological toll. Effective care must be rooted in evidence, with compassion for both the body and the mind."
"For too long, people have carried the weight of shame when what they needed was care. At this summit, we are rewriting that story — one rooted in love, science, and the belief that every person deserves access to evidence-based treatment." — Sandra Elia, Chair, Obesity Matters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis
- Approximately 3,800 people in Canada are now eligible for ALYFTREK, with up to 60 people potentially eligible for a medicine that treats the underlying cause of their disease for the first time - TORONTO, July 22, 2025 /CNW/ - Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for Pr ALYFTREK TM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. ALYFTREK brings a potentially transformative therapy to up to 60 people living with CF in Canada who were not previously eligible for a CFTR modulator. As the first once-daily CFTR modulator, ALYFTREK may also provide a new treatment option and flexibility for approximately 3,800 people given the need to take CFTR modulators with fat-containing food. "ALYFTREK represents the next generation of CFTR modulator treatment and is a testament to our long-standing goal to address the underlying cause of cystic fibrosis, treat more people living with CF, and bring more people to normal levels of CFTR function," said Michael Siauw, General Manager at Vertex Pharmaceuticals (Canada) Incorporated. "With once-daily dosing, eligibility in 113 additional mutations, and the potential to lower sweat chloride levels even further, ALYFTREK brings us one step closer to achieving this goal." This approval is based on a comprehensive Phase 3 pivotal program, including more than 1,000 patients across more than 20 countries and more than 200 sites. The Phase 3 studies in people with CF ages 12 years and older met their primary endpoint (non-inferiority on absolute change from baseline in ppFEV 1 compared to TRIKAFTA) and all key secondary endpoints (including absolute change from baseline in sweat chloride [SwCl] compared to TRIKAFTA). In the Phase 3 study of children with CF ages 6-11 years, ALYFTREK demonstrated safety, the primary endpoint. Secondary endpoints, such as absolute change from baseline in ppFEV 1 and absolute change from baseline in SwCl, demonstrate the benefit of ALYFTREK in this age group. ALYFTREK was generally well tolerated across all studies. "For Canadian patients and families, the approval of ALYFTREK represents significant progress towards improved care," said Dr. Bradley Quon, Medical and Research Director of the Adult Cystic Fibrosis Program at St. Paul's Hospital, and Associate Professor of Medicine in the Faculty of Medicine at the University of British Columbia. "Lower levels of sweat chloride combined with the convenience of a once-a-day treatment provides a new option that has the potential to both improve CFTR function and reduce treatment burden." ALYFTREK is currently approved in the U.S., UK and European Union and is under regulatory review in Switzerland, Australia and New Zealand. About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 109,000 people, including 94,000 people in North America, Europe and Australia. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving. Today Vertex CF medicines are treating over 75,000 people with CF in more than 60 countries on six continents. This represents 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy. Sweat chloride, which measures CFTR function, is used to diagnose CF. The diagnostic threshold for CF is SwCl ≥60 mmol/L, while levels between 30-59 indicate CF is possible and more testing may be needed to make the diagnosis of CF. A SwCl level of <30 mmol/L is seen in people who carry one copy of a CFTR gene mutation but do not have any manifestation of disease (carriers). At a population level, higher levels of SwCl are associated with more severe disease. Restoring CFTR function leads to lower levels of SwCl. Restoring SwCl levels below 30 mmol/L has long been the ultimate treatment goal for Vertex, as levels below 30 mmol/L are considered normal and are typical of CF carriers who do not have disease. About ALYFTREK TM (vanzacaftor/tezacaftor/deutivacaftor) In people with CF, mutations in the CFTR gene lead to decreased quantity and/or function of the CFTR protein channel at the cell surface. Vanzacaftor and tezacaftor are designed to increase the amount of CFTR protein at the cell surface by facilitating the processing and trafficking of the CFTR protein. Deutivacaftor is a potentiator designed to increase the channel open probability of the CFTR protein delivered to the cell surface to improve the flow of salt and water across the cell membrane. ALYFTREK is approved in the U.S., UK, and Canada for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene. ALYFTREK is approved in the European Union for the treatment of CF in patients ages 6 years and older who have at least one non-class I mutation in the CFTR gene. Boxed Warning Elevated transaminases have been observed in some patients treated with ALYFTREK. Cases of liver failure leading to transplantation and death have been reported in patients with and without a history of liver disease taking a fixed dose combination drug containing elexacaftor, tezacaftor, and ivacaftor, which contains one same (tezacaftor) and one similar (ivacaftor) active ingredient as ALYFTREK. Liver injury has primarily been reported within the first 6 months following initiation of elexacaftor/tezacaftor/ivacaftor. See full ALYFTREK Product Monograph for further details. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Michael Siauw and Dr. Bradley Quon, and statements regarding the anticipated eligible patient population in Canada and expectations for the ALYFTREK regulatory submissions in Switzerland, Australia and New Zealand. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, or other reasons, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Vertex Pharmaceuticals Incorporated Investors: [email protected] Media: [email protected] or Canada: +1 647-790-1600 SOURCE Vertex Pharmaceuticals (Canada) Inc.
Cision Canada
4 hours ago
- Cision Canada
Government of Canada improves access to health services for Francophone minority communities Français
MONCTON, NB, July 22, 2025 /CNW/ - Today, the Honourable Marjorie Michel, Minister of Health, accompanied by the Honourable Ginette Petitpas Taylor, Member of Parliament for Moncton—Dieppe, announced more than $78 million in funding over five years to seven organizations including five Atlantic post-secondary training institutions to improve access to health services in French for Francophone communities. These investments will support innovative projects to improve health services in French through the Official Languages Health Program (OLHP). Initiatives include increasing access to care, improving recruitment, internship and placement opportunities in Francophone communities as well as training in francophone post-secondary health programs. The Government of Canda will continue working with partners to improve access to health care services for everyone, including services in the official language of their choice. Quotes "Everyone in Canada should have access to health services in their official language of choice, regardless of where they live. When it comes to health care, a language barrier can lead to a life-or-death situation. This is why the Government of Canada is supporting projects that will improve access to health services for Francophones and Anglophones living in minority communities in Canada." The Honourable Marjorie Michel Minister of Health "As a proud Atlantic Canadian, I know how vital it is for Francophones in minority communities to access health care in their language of choice. This funding will contribute to improved access to more inclusive and effective care — ensuring official languages are supported within our health care system." The Honourable Ginette Petitpas Taylor Member of Parliament for Moncton—Dieppe "Our two official languages are at the heart of our identity, uniting us from coast to coast to coast and making us stronger together. As a government, we are taking concrete action to ensure that Canadians—no matter where they live—can access health services in the official language of their choice. I am pleased that this funding will support projects that strengthen our bilingual identity, not only in the Atlantic region but right across Canada." The Honourable Steven Guilbeault Minister of Canadian Identity and Culture and Minister responsible for Official Languages "Health is essential to the vitality of Francophone and Acadian minority communities, and they should have access to quality health services in their own language. Société Santé en français is proud to work with Canada's 16 French-language health networks and hundreds of other health partners to develop French-language health services across Canada." Antoine Désilets Executive Director, Société Santé en français "The importance of preparing the next generation of French-speaking health care workers, from recruitment to professional integration in Francophone minority communities, cannot be overstated. Health Canada's contribution will leverage the Association des collèges et universités de la francophonie canadienne's (ACUFC) ability to support postsecondary institutions that are members of the Consortium national de formation en santé in their efforts to increase the number of health professionals providing French-language services. It will also allow our network to continue to overcome existing barriers and ensure that Canadians have access to equitable health services in the language of their choice." Martin Normand President and Chief Executive Officer, Association des collèges et universités de la francophonie canadienne - Consortium national de formation en santé "The financial support from the federal government represents much more than a simple investment in health training: it is a concrete gesture in favor of improving access to French-language health services in our Francophone minority communities. At the Université de Moncton, this support will strengthen our capacity to offer training in targeted health programs. We are proud to be part of a national network of 16 post-secondary institutions — a group that fosters collaboration, shares expertise, and promotes our programs. Together, we are helping to train the next generation of competent, committed professionals ready to meet the needs of French-language healthcare across the country." Dr. Denis Prud'homme President and Vice-Chancellor of the Université de Moncton Quick Facts The OLHP was launched in 2003 and receives funding through the Government of Canada's Action Plan for Official Languages. The Program supports non-profit organizations, post-secondary institutions and provincial and territorial governments that aim to improve access to health services for official language minority communities (OLMC) - Francophones living outside Quebec and English-speaking communities in Quebec. The " Action Plan for Official Languages 2023–2028: Protection-Promotion-Collaboration" announced that, in addition to existing funding of $192.2 million over five years, Health Canada's OLHP will also receive $14.5 million over five years (for a total of $206.7 million over five years). This additional funding will support non-profit organizations, provincial and territorial governments and post-secondary institutions that serve OLMCs to train and retain bilingual health professionals, support health networking initiatives as well as innovative projects. Budget 2023 outlined the Government's plan to invest close to $200 billion over 10 years, including $46.2 billion in new funding to provinces and territories to strengthen Canada's public health care system. This includes $25 billion of funding through tailored bilateral agreements to meet the specific needs of each province and territory. Associated Links SOURCE Health Canada (HC)
Cision Canada
5 hours ago
- Cision Canada
Natural Pastures Cheese Company brand Mount Becher Buffalo Medium Cheese recalled due to Listeria monocytogenes
OTTAWA, ON, July 22, 2025 /CNW/ - Product: Mount Becher Buffalo Medium Cheese Issue: Food - Microbial contamination - Listeria Distribution British Columbia Ontario Online link SOURCE Canadian Food Inspection Agency (CFIA)
